-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
CAN106 showed good dose-dependent and pharmacokinetic properties with a terminal elimination half-life of approximately 32 days
At the same time, Beihai Kangcheng's clinical trial application in China has been approved, and the Phase Ib/II trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in China has been approved
Xue Qun, Ph.
Dr.
Research Introduction
The study, titled "Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of CAN106 Intravenous (IV) in Healthy Subjects with Single Ascending Dose (SAD)", is a A single-center, single-dose escalation study involving 31 healthy subjects (23 receiving CAN106 and 8 receiving placebo)
About CAN 106
CAN106 is an innovative long-acting recombinant humanized monoclonal antibody that binds and neutralizes C5, a complement system protein, thereby preventing the formation of the membrane attack complex (MAC), which causes cell lysis (destruction) and other symptoms associated with PNH
Introduction to Paroxysmal Nocturnal Hemoglobinuria ( PNH )
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and fatal complement system disorder
About Beihai Kangcheng Pharmaceutical Co.
Beihai Kangcheng Pharmaceutical Co.
Beihai Kangcheng currently has a comprehensive and differentiated pipeline of 13 drug assets with significant market potential, targeting some of the most prevalent rare disease and rare tumor indications
Beihai Kangcheng strategically combines global collaboration with in-house research to build a diverse drug portfolio, while investing in next-generation gene therapy technologies for rare disease treatment
For more information about Beihai Kangcheng, please go to:statements made herein relate only to events or information as of the date of the statements made herein
